Celsus becomes Akari after trial failure
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Akari, Peak Bio Hatch Merger Plan To Survive Together
Deal snapshot: Akari, which has stayed afloat through small financings in recent years, and Peak Bio, after going public via the SPAC route in 2022, will merge as equals and then prioritize their pipeline.
Akari Hopes Tick-Based Drug Will Be Safer, Cheaper Than Alexion's Soliris
Akari Therapeutics is looking to ticks to provide a new therapy that it hopes will offer a safer and cheaper alternative to Alexion Pharmaceuticals' Soliris for some rare orphan diseases.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.